XNCR logo

Xencor, Inc.

XNCR

XNCR: Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.

more

Show XNCR Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of XNCR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by XNCR's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Heterodimeric antibodies that bind cd3 and cldn6 Aug. 29, 2023
  • Patent Title: Optimized antibody variable regions Aug. 08, 2023
  • Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Jun. 13, 2023
  • Patent Title: Il-12 heterodimeric fc-fusion proteins May. 23, 2023
  • Patent Title: Heterodimeric proteins Apr. 25, 2023
  • Patent Title: Heterodimeric antibodies that bind cd3 and psma Apr. 11, 2023
  • Patent Title: Optimized antibodies that target cd19 Apr. 04, 2023
  • Patent Title: Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains Apr. 04, 2023
  • Patent Title: Anti-cd28 compositions Feb. 28, 2023
  • Patent Title: Bispecific heterodimeric fusion proteins containing il-15-il-15ralpha fc-fusion proteins and immune checkpoint antibody fragments Feb. 21, 2023
  • Patent Title: Compositions and methods for treating ige-mediated disorders Jan. 31, 2023
  • Patent Title: Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof Dec. 13, 2022
  • Patent Title: Il-7-fc-fusion proteins Nov. 29, 2022
  • Patent Title: Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains Nov. 22, 2022
  • Patent Title: Bispecific checkpoint inhibitor antibodies Nov. 08, 2022
  • Patent Title: Heterodimeric antibodies that bind enpp3 and cd3 Oct. 18, 2022
  • Patent Title: Methods and compositions for inhibiting cd32b expressing cells Sep. 20, 2022
  • Patent Title: Methods and compositions for inhibiting cd32b expressing cells Sep. 06, 2022
  • Patent Title: Heterodimeric fc variants Aug. 02, 2022
  • Patent Title: Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof Jul. 05, 2022
  • Patent Title: Methods of treating neurological diseases Jun. 21, 2022
  • Patent Title: Methods and compositions for inhibiting cd32b expressing cells in igg4-related diseases Jun. 21, 2022
  • Patent Title: Il-12 heterodimeric fc-fusion proteins Jun. 14, 2022
  • Patent Title: Ctla4-ig immunoadhesins Jun. 07, 2022
  • Patent Title: Heterodimeric antibodies that bind cd3 and cd38 Jun. 07, 2022
  • Patent Title: Engineered il-2 fc fusion proteins May. 03, 2022
  • Patent Title: Bispecific and monospecific antibodies using novel anti-pd-1 sequences Apr. 26, 2022
  • Patent Title: Heterodimeric proteins Apr. 12, 2022
  • Patent Title: Ctla4-ig immunoadhesins Feb. 22, 2022
  • Patent Title: Bispecific checkpoint inhibitor antibodies Feb. 01, 2022
  • Patent Title: Heterodimeric antibodies that bind somatostatin receptor 2 Jan. 18, 2022
  • Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Jan. 18, 2022
  • Patent Title: Fc variants with altered binding to fcrn Dec. 14, 2021
  • Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Sep. 07, 2021
  • Patent Title: Modulation of t cells with bispecific antibodies and fc fusions Aug. 17, 2021
  • Patent Title: Targeted heterodimeric fc fusion proteins containing il-15 il-15alpha and antigen binding domains Aug. 10, 2021
  • Patent Title: Optimized antibody variable regions Jul. 06, 2021
  • Patent Title: Heterodimeric antibodies that bind fibroblast activation protein Apr. 20, 2021
  • Patent Title: Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors Apr. 20, 2021
  • Patent Title: Optimized anti-cd3 variable regions Apr. 06, 2021
  • Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Feb. 09, 2021
  • Patent Title: Heterodimeric antibodies that bind cd3 and tumor antigens Jan. 12, 2021
  • Patent Title: Heterodimeric proteins Dec. 08, 2020
  • Patent Title: Bispecific antibodies that bind to cd38 and cd3 Dec. 08, 2020
  • Patent Title: Heterodimeric human igg1 polypeptides with isoelectric point modifications Dec. 01, 2020
  • Patent Title: Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors Oct. 06, 2020
  • Patent Title: Bispecific checkpoint inhibitor antibodies Sep. 29, 2020
  • Patent Title: Heterodimeric proteins Aug. 11, 2020
  • Patent Title: Heterodimeric proteins Aug. 11, 2020
  • Patent Title: Fc variants with increased affinity for fcγriic Mar. 10, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of XNCR in WallStreetBets Daily Discussion

XNCR News

Recent insights relating to XNCR

CNBC Recommendations

Recent picks made for XNCR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in XNCR

Corporate Flights

Flights by private jets registered to XNCR